Lessons from a BACE1 inhibitor trial: Off-site but not off base

Alzheimer's and Dementia

Volumn 10, Issue 5, 2014, Pages S411-S419

  Lahiri, Debomoy K ^a,b   Maloney, Bryan ^a   Long, Justin M ^a   Greig, Nigel H ^c  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY   (United States)

^c NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

Aging; Animal model; Brain disorder; CNS; Dementia; Demyelination; Drug trial; Human studies; Liver damage; Melatonin; Neuronal death; ROS; Secretase; Sialylation; Side effects

Indexed keywords

ADAM10 ENDOPEPTIDASE; AMYLOID BETA PROTEIN; BETA SECRETASE 1; BETA SECRETASE INHIBITOR; LY 2886721; MESSENGER RNA; NEU DIFFERENTIATION FACTOR; PARACETAMOL; UNCLASSIFIED DRUG; ASPARTIC PROTEINASE; BACE1 PROTEIN, HUMAN; BACE1 PROTEIN, MOUSE; FUSED HETEROCYCLIC RINGS; N-(3-(2-AMINO-4A,5,7,7A-TETRAHYDRO-4H-FURO(3,4-D)(1,3)THIAZIN-7A-YL)-4-FLUOROPHENYL)-5-FLUOROPICOLINAMIDE; NOOTROPIC AGENT; PICOLINIC ACID DERIVATIVE; PROTEINASE INHIBITOR; SECRETASE;

ACUTE LIVER FAILURE; ALZHEIMER DISEASE; CATALYSIS; CELL DAMAGE; DRUG EFFECT; DRUG METABOLISM; DRUG TARGETING; ENZYME INHIBITION; HUMAN; LIVER TOXICITY; NONHUMAN; OFF TARGET DRUG EFFECT; PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN CLEAVAGE; REVIEW; TOXIC HEPATITIS; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; BRAIN; CLINICAL TRIAL (TOPIC); DISEASE MODEL; DRUG EFFECTS; GENETICS; KNOCKOUT MOUSE; LIVER; METABOLISM; PATHOPHYSIOLOGY;

ALZHEIMER DISEASE; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ASPARTIC ACID ENDOPEPTIDASES; BRAIN; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; HETEROCYCLIC COMPOUNDS, 2-RING; HUMANS; LIVER; MICE, KNOCKOUT; MODELS, BIOLOGICAL; NOOTROPIC AGENTS; PICOLINIC ACIDS; PROTEASE INHIBITORS;

EID: 84908254254     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2013.11.004     Document Type: Article

References (63)

1. W. Thies, and L. Bleiler 2013 Alzheimer's disease facts and figures Alzheimers Dement 9 2013 208 245
2. J. Wu, M.R. Basha, B. Brock, D.P. Cox, F. Cardozo-Pelaez, and C.A. McPherson Alzheimer's disease (AD)-like pathology in aged monkeys after infantile exposure to environmental metal lead (Pb): evidence for a developmental origin and environmental link for AD J Neurosci 28 2008 3 9
3. D.K. Lahiri, B. Maloney, and N.H. Zawia The LEARn model: an epigenetic explanation for idiopathic neurobiological diseases Mol Psychiatry 14 2009 992 1003
4. A. Corbett, and C. Ballard New and emerging treatments for Alzheimer's disease Expert Opin Emerg Drugs 17 2012 147 156
5. Y. Huang, and L. Mucke Alzheimer mechanisms and therapeutic strategies Cell 148 2012 1204 1222
6. J.A. Bailey, B. Ray, N.H. Greig, and D.K. Lahiri Rivastigmine lowers Abeta and increases sAPPalpha levels, which parallel elevated synaptic markers and metabolic activity in degenerating primary rat neurons PLoS One 6 2011 e21954
7. L.S. Schneider, and D.K. Lahiri The perils of Alzheimer's drug development Curr Alzheimer Res 6 2009 77 78
8. R.E. Becker, and N.H. Greig Why so few drugs for Alzheimer's disease? Are methods failing drugs? Curr Alzheimer Res 7 2010 642 651
9. K. Sambamurti, N.H. Greig, T. Utsuki, E.L. Barnwell, E. Sharma, and C. Mazell Targets for AD treatment: conflicting messages from gamma-secretase inhibitors J Neurochem 117 2011 359 374
10. J. Hardy The amyloid hypothesis for Alzheimer's disease: a critical reappraisal J Neurochem 110 2009 1129 1134
11. R. Vassar, B.D. Bennett, S. Babu-Khan, S. Kahn, E.A. Mendiaz, and P. Denis Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE Science 286 1999 735 741
12. Y. Li, W. Zhou, Y. Tong, G. He, and W. Song Control of APP processing and Abeta generation level by BACE1 enzymatic activity and transcription FASEB J 20 2006 285 292
13. K. Sambamurti, R. Kinsey, B. Maloney, Y.W. Ge, and D.K. Lahiri Gene structure and organization of the human beta-secretase (BACE) promoter FASEB J 18 2004 1034 1036
14. Y.-W. Ge, B. Maloney, K. Sambamurti, and D.K. Lahiri Functional characterization of the 5' flanking region of the BACE gene: identification of a 91 bp fragment involved in basal level of BACE promoter expression FASEB J 18 2004 1037 1039
15. D.K. Lahiri, Y.W. Ge, J.T. Rogers, K. Sambamurti, N.H. Greig, and B. Maloney Taking down the unindicted co-conspirators of amyloid beta-peptide-mediated neuronal death: shared gene regulation of BACE1 and APP genes interacting with CREB, Fe65 and YY1 transcription factors Curr Alzheimer Res 3 2006 475 483
16. D.K. Lahiri, B. Maloney, and W. Ge Y BACE1 gene promoter is differentially regulated: detection of a novel promoter region for its cell type-specific regulation J Mol Neurosci 28 2006 193 210
17. Y. Wen, W.H. Yu, B. Maloney, J. Bailey, J. Ma, and I. Marie Transcriptional regulation of beta-secretase by p25/cdk5 leads to enhanced amyloidogenic processing Neuron 57 2008 680 690
18. B.P. Imbimbo, F. Panza, V. Frisardi, V. Solfrizzi, G. D'Onofrio, and G. Logroscino Therapeutic intervention for Alzheimer's disease with gamma-secretase inhibitors: still a viable option? Expert Opin Investig Drugs 20 2011 325 341
19. Y. Luo, B. Bolon, S. Kahn, B.D. Bennett, S. Babu-Khan, and P. Denis Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation Nat Neurosci 4 2001 231 232
20. S.M. Harrison, A.J. Harper, J. Hawkins, G. Duddy, E. Grau, and P.L. Pugh BACE1 (beta-secretase) transgenic and knockout mice: identification of neurochemical deficits and behavioral changes Mol Cell Neurosci 24 2003 646 655
21. Rogers MB. Lilly halts Phase 2 trial of BACE inhibitor due to liver toxicity. Alzheimer Research Forum, 2013. Available at: http://www.alzforum.org/new/detail.asp?id=3522. Accessed October 28, 2013.
22. P.J. Meakin, A.J. Harper, D.L. Hamilton, J. Gallagher, A.D. McNeilly, and L.A. Burgess Reduction in BACE1 decreases body weight, protects against diet-induced obesity and enhances insulin sensitivity in mice Biochem J 441 2012 285 296
23. M. Willem, A.N. Garratt, B. Novak, M. Citron, S. Kaufmann, and A. Rittger Control of peripheral nerve myelination by the beta-secretase BACE1 Science 314 2006 664 666
24. X. Hu, C.W. Hicks, W. He, P. Wong, W.B. Macklin, and B.D. Trapp Bace1 modulates myelination in the central and peripheral nervous system Nat Neurosci 9 2006 1520 1525
25. C. Cheret, M. Willem, F.R. Fricker, H. Wende, A. Wulf-Goldenberg, and S. Tahirovic Bace1 and Neuregulin-1 cooperate to control formation and maintenance of muscle spindles EMBO J 32 2013 2015 2028
26. P.C. May, R.A. Dean, S.L. Lowe, F. Martenyi, S.M. Sheehan, and L.N. Boggs Robust central reduction of amyloid-beta in humans with an orally available, non-peptidic beta-secretase inhibitor J Neurosci 31 2011 16507 16516
27. D. Fleck, F. van Bebber, A. Colombo, C. Galante, B.M. Schwenk, and L. Rabe Dual cleavage of neuregulin 1 type III by BACE1 and ADAM17 liberates its EGF-like domain and allows paracrine signaling J Neurosci 33 2013 7856 7869
28. F. van Bebber, A. Hruscha, M. Willem, B. Schmid, and C. Haass Loss of Bace2 in zebrafish affects melanocyte migration and is distinct from Bace1 knock out phenotypes J Neurochem 127 2013 471 481
29. S. Kitazume, R. Oka, K. Ogawa, S. Futakawa, Y. Hagiwara, and H. Takikawa Molecular insights into beta-galactoside alpha2,6-sialyltransferase secretion in vivo Glycobiology 19 2009 479 487
30. S. Kitazume, K. Nakagawa, R. Oka, Y. Tachida, K. Ogawa, and Y. Luo In vivo cleavage of alpha2,6-sialyltransferase by Alzheimer beta-secretase J Biol Chem 280 2005 8589 8595
31. S. Kitazume, Y. Tachida, R. Oka, K. Shirotani, T.C. Saido, and Y. Hashimoto Alzheimer's beta-secretase, beta-site amyloid precursor protein-cleaving enzyme, is responsible for cleavage secretion of a Golgi-resident sialyltransferase Proc Natl Acad Sci USA 98 2001 13554 13559
32. M. Lee, H.J. Lee, S. Bae, and Y.S. Lee Protein sialylation by sialyltransferase involves radiation resistance Mol Cancer Res 6 2008 1316 1325
33. D.K. Lahiri, D.K. Sokol, C. Erickson, B. Ray, C.Y. Ho, and B. Maloney Autism as early neurodevelopmental disorder: evidence for an sAPPalpha-mediated anabolic pathway Front Cell Neurosci 7 2013 94
34. A. Solans, X. Estivill, and S. de La Luna A new aspartyl protease on 21q22.3, BACE2, is highly similar to Alzheimer's amyloid precursor protein beta-secretase Cytogenet Cell Genet 89 2000 177 184
35. I. Schechter, and E. Ziv Kinetic properties of cathepsin D and BACE 1 indicate the need to search for additional beta-secretase candidate(s) Biol Chem 389 2008 313 320
36. R.Y. Liu, J.N. Zhou, J. van Heerikhuize, M.A. Hofman, and D.F. Swaab Decreased melatonin levels in postmortem cerebrospinal fluid in relation to aging, Alzheimer's disease, and apolipoprotein E-epsilon4/4 genotype J Clin Endrocrinol Metab 84 1999 323 327
37. D.K. Lahiri, Y.W. Ge, E.H. Sharman, and S.C. Bondy Age-related changes in serum melatonin in mice: higher levels of combined melatonin and 6-hydroxymelatonin sulfate in the cerebral cortex than serum, heart, liver and kidney tissues J Pineal Res 36 2004 217 223
38. F. Ponten, K. Jirstrom, and M. Uhlen The Human Protein Atlas - a tool for pathology J Pathol 216 2008 387 393
39. W. Norris, A.H. Paredes, and J.H. Lewis Drug-induced liver injury in 2007 Curr Opin Gastroenterol 24 2008 287 297
40. L. Leung, A.S. Kalgutkar, and R.S. Obach Metabolic activation in drug-induced liver injury Drug Metab Rev 44 2012 18 33
41. A.S. Kalgutkar, I. Gardner, R.S. Obach, C.L. Shaffer, E. Callegari, and K.R. Henne A comprehensive listing of bioactivation pathways of organic functional groups Curr Drug Metab 6 2005 161 225
42. J.L. Bolton, M.A. Trush, T.M. Penning, G. Dryhurst, and T.J. Monks Role of quinones in toxicology Chem Res Toxicol 13 2000 135 160
43. T.J. Monks, and D.C. Jones The metabolism and toxicity of quinones, quinonimines, quinone methides, and quinonethioethers Curr Drug Metab 3 2002 425 438
44. D.P. Williams Toxicophores: investigations in drug safety Toxicology 226 2006 1 11
45. W.W. Johnson Many drugs and phytochemicals can be activated to biological reactive intermediates Curr Drug Metab 9 2008 344 351
46. H. Jaeschke, and M.L. Bajt Intracellular signaling mechanisms of acetaminophen-induced liver cell death Toxicol Sci 89 2006 31 41
47. S.H. Hussaini, and E.A. Farrington Idiosyncratic drug-induced liver injury: an update on the 2007 overview Expert Opin Drug Saf 13 2014 67 81
48. A. Corsini, P. Ganey, C. Ju, N. Kaplowitz, D. Pessayre, and R. Roth Current challenges and controversies in drug-induced liver injury Drug Saf 35 2012 1099 1117
49. M. Vinken, M. Maes, T. Vanhaecke, and V. Rogiers Drug-induced liver injury: mechanisms, types and biomarkers Curr Med Chem 20 2013 3011 3021
50. A. Cardenas, J.C. Restrepo, F. Sierra, and G. Correa Acute hepatitis due to shen-min: a herbal product derived from Polygonum multiflorum J Clin Gastroenterol 40 2006 629 632
51. D.B. Njoku Suppressive and pro-inflammatory roles for IL-4 in the pathogenesis of experimental drug-induced liver injury: a review Expert Opin Drug Metab Toxicol 6 2010 519 531
52. S.D. Larson, L.N. Jackson, L.A. Chen, P.G. Rychahou, and B.M. Evers Effectiveness of siRNA uptake in target tissues by various delivery methods Surgery 142 2007 262 269
53. L. Alvarez-Erviti, Y. Seow, H. Yin, C. Betts, S. Lakhal, and M.J. Wood Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes Nat Biotechnol 29 2011 341 345
54. D.P. Bartel MicroRNAs: target recognition and regulatory functions Cell 136 2009 215 233
55. J.M. Long, and D.K. Lahiri Advances in MicroRNA experimental approaches to study physiological regulation of gene products implicated in CNS disorders Exp Neurol 235 2012 402 418
56. K.N. Holohan, D.K. Lahiri, B.P. Schneider, T. Foroud, and A.J. Saykin Functional microRNAs in Alzheimer's disease and cancer: differential regulation of common mechanisms and pathway Front Genet 3 2012 323
57. J.M. Long, and D.K. Lahiri MicroRNA-101 downregulates Alzheimer's amyloid-beta precursor protein levels in human cell cultures and is differentially expressed Biochem Biophys Res Commun 404 2011 889 895
58. J.M. Long, B. Ray, and D.K. Lahiri MicroRNA-153 physiologically inhibits expression of amyloid-beta precursor protein in cultured human fetal brain cells and is dysregulated in a subset of Alzheimer disease patients J Biol Chem 287 2012 31298 31310
59. Long JM, Ray B, Lahiri DK. Human microRNA-339-35p negatively regulates β-site amyloid precursor protein cleaving enzyme 1 (BACE1) in human primary brain cultures and is dysregulated in a subset of Alzheimer's disease subjects. J Biol Chem (in press).
60. D.K. Lahiri, B. Maloney, M.R. Basha, Y.W. Ge, and N.H. Zawia How and when environmental agents and dietary factors affect the course of Alzheimer's disease: the "LEARn" model (latent early-life associated regulation) may explain the triggering of AD Curr Alzheimer Res 4 2007 219 228
61. D.K. Lahiri Prions: a piece of the puzzle? Science 337 2012 1172
62. Merck Presents Findings from Phase 1b Study of Investigational BACE Inhibitor, MK-8931, in Patients with Alzheimer's Disease. Available at: http://www.mercknewsroom.com/press-release/alzheimers-disease/merck-presents-findings-phase-1b-study-investigational-bace-inhibit. Accessed October 28, 2013.
63. An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738) (EPOCH). Available at: http://clinicaltrials.gov/show/NCT01739348. Accessed October 28, 2013.